Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C24H47NO3
CAS Number:
Molecular Weight:
397.63
MDL number:
UNSPSC Code:
12352211
NACRES:
NA.25
SMILES string
OC[C@]([H])(NC(CCCCC)=O)[C@]([H])(O)/C=C/CCCCCCCCCCCCC
InChI
1S/C24H47NO3/c1-3-5-7-8-9-10-11-12-13-14-15-16-18-19-23(27)22(21-26)25-24(28)20-17-6-4-2/h18-19,22-23,26-27H,3-17,20-21H2,1-2H3,(H,25,28)/b19-18+
InChI key
NPRJSFWNFTXXQC-VHEBQXMUSA-N
assay
>99% (TLC)
form
powder
packaging
pkg of 1 × 10 mg (860506P-10mg), pkg of 1 × 5 mg (860506P-5mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand
lipid type
sphingolipids
shipped in
dry ice
storage temp.
−20°C
General description
C6 Ceramide (d18:1/6:0) is a short chain and a cell permeable ceramide. It comprises amino alcoholic chain attached to fatty acyl chain via an amide linkage.
Application
C6 Ceramide (d18:1/6:0) has been used as a chemotherapeutic agent to test its anti-tumor effect in breast cancer cells and ovarian cancer cell lines. It has also been used to test chemo-sensitization effects in cancer cells.
Biochem/physiol Actions
C6 Ceramide (d18:1/6:0) is involved in inhibiting proliferation and inducing apoptosis. When used in combination with acid ceramidase inhibitor DM102, [(2R,3Z)-N-(1-hydroxyoctadec-3-en-2-yl)pivaloylamide], it favors cell death in human breast cancer cells lines. C6 Ceramide may serve as an adjunct in chemotherapy. It elicits anti-tumor effects via AKT (serine/threonine-specific protein kinase) dephosphorylation and α-tubulin acetylation.
Packaging
5 mL Amber Glass Screw Cap Vial (860506P-10mg)
5 mL Amber Glass Screw Cap Vial (860506P-5mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Q-y Zhu et al.
Cell death & disease, 2, e117-e117 (2011-03-04)
Histone deacetylase inhibitors (HDACIs) have shown promising anti-tumor effects for a variety of malignancies, however, many tumors are reportedly resistant to them. In this study, we made a novel discovery that co-administration of HDACIs (Trichostatin A (TSA) and others) and
C6-ceramide and targeted inhibition of acid ceramidase induce synergistic decreases in breast cancer cell growth
Flowers M, et al.
Breast Cancer Research and Treatment, 133(2), 447-458 (2012)
C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and alpha-tubulin hyperacetylation both in vitro and in vivo
Zhu QY, et al.
Cell Death & Disease, 2(1), e117-e117 (2011)
Exogenous cell-permeable C6 ceramide sensitizes multiple cancer cell lines to Doxorubicin-induced apoptosis by promoting AMPK activation and mTORC1 inhibition
Ji C, et al.
Oncogene, 29(50), 6557-6557 (2010)
C6 ceramide dramatically enhances docetaxel-induced growth inhibition and apoptosis in cultured breast cancer cells: a mechanism study
Yang L, et al.
Experimental Cell Research, 332(1), 47-59 (2015)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service